Summary
225 mg Procarbazine administered by 15 intraperitoneal injections in R strain female rats induced malignant tumors in every rat after a median latency of 301 days: mammary, uterine and ear-duct tumors were obtained after a latent period of 270, 377, and 244 days respectively.
Zusammenfassung
225 mg Procarbazin wurden in 15 intraperitonealen Injektionen weiblichen Ratten des R-Stammes verabreicht. Nach einer mittleren Latenzzeit von 301 Tagen entstanden in jedem Tier Tumoren, und zwar in Mamma, Uterus und Gehörgang nach 270, 377 und 244 Tagen in den genannten einzelnen Lokalisationen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bollag,W.: The tumor-inhibitory effects of the methylhydrazine derivative Ro 4-6467/1 (NSC-77213). Cancer Chemother. Eep. 33, 1–4 (1963)
Bollag,W., Grunberg,E.: Tumor-inhibitory effects of a new class of cytotoxic agents: methylhydrazine derivatives. Experientia (Basel) 19, 130–131 (1963)
Boyland,E.: Cited by Weisburger and Weisburger. In: Busch,H. (Ed.): Methods in Cancer Research, Vol. I, p. 378, New York: Academic Press 1967
Heuson,J.C., Heimann,R.: Ibenzmethyzin (Natulan) a highly effective mammary carcinogen in the Huggins system. Europ. J. Cancer 2, 385–386 (1966), Letter to the Editor
Kelly,M.G., O'Gara,R.W., Gadekar,K., Yancey,S.T., Oliverio,V.T.: Carcinogenic activity of a new antitumor agent. N-Isopropyl-α-(2-methylhydrazino)-p-toluamide hydrochloride (NSC-77213). Cancer Chemother. Rep. 39, 77–80 (1964)
Kelly,M.G., O'Gara,R.W., Yancey,S.T., Botkin,C.: Induction of tumors in rats with procarbazine hydrochloride. J. nat. Cancer Inst. 40, 1027–1051 (1968)
Kelly,M.G., O'Gara,R.W., Yancey,S.T., Gadekar,K., Botkin,C., Oliverio,V.T.: Comparative carcinogenicity of N-Isopropyl-α-(2-Methylhydrazino)-p-Toluamide HCl (Procarbazine Hydrochloride), its degradation products, other hydrazines, and isonicotinic acid hydrazide. J. nat. Cancer Inst. 42, 337–344 (1969)
Kummer,H., Bucher,U.: Erfahrungen mit einem neuen Cytostaticum der Methyl-Hydrazinreihe (Natulan). Mit besonderer Berücksichtigung der hämatologischen Nebenwirkungen. Schweiz. med. Wschr. 95, 1233–1240 (1965)
Martz,G.: Premières observations cliniques avec une nouvelle substance antimitotique: la méthylhydrazine „Natulan”. Méd. Hyg. 22, 826–827 (1964)
Scharf,H., Krüger,C., Karsten,C.: Studies of the immunosuppressive properties of cytostatic agents in rats, with particular attention to carcinogenic activity. Cancer Chemother. Abstr. 11, 111 (1970); Arzneimittelforsch. 20, 1467–1470 (1970)
Schmähl,D.: Perspektiven der Krebs-Chemotherapie. Geburts. Frauenheilk. 30, 13–24 (1970)
Schmähl,D., Osswald,H.: Experimental studies of the carcinogenic activity of antitumor and immunosuppressive agents. Cancer Chemother. Abstr. 11, 111 (1970); Arzneimittelforsch. forsch. 20, 1461–1467 (1970)
Witte,S., Martin,H., Schubert,J.C.F.: Über die cytostatische Therapie mit einem Methylhydrazinderivat. Schweiz. med. Wsch. 96, 93–99 (1966)
Author information
Authors and Affiliations
Additional information
Centre d'Etude de l'Energie Nucléaire, mol.
Rights and permissions
About this article
Cite this article
Deckers, C., Deckers-Passau, L., Maisin, J. et al. Carcinogenicity of Procarbazine. Z. Krebsforsch. 81, 79–84 (1974). https://doi.org/10.1007/BF00304148
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00304148